查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938531

光學切片市場 - 全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Optical Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technique, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球光學切片市場預計將從 2025 年的 14.6 億美元成長到 2031 年的 23.2 億美元，複合年成長率為 8.02%。

光學活體組織切片是一種非侵入性診斷方法，它利用光與組織的相互作用來獲取即時病理數據，無需進行物理組織取樣。市場成長的主要驅動力是腫瘤疾病發生率的上升以及早期疾病檢測的重要性，而早期疾病檢測需要頻繁且微創的診斷程序。根據美國癌症協會預測，到2024年，美國預計將新增2,001,140例癌症病例，日益加重的疾病負擔推動了對能夠提供即時結果以迅速制定治療方案的快速診斷方法的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 14.6億美元
市場規模：2031年 23.2億美元
複合年成長率：2026-2031年 8.02%
成長最快的細分市場 光譜學
最大的市場 北美洲

儘管光學成像設備具有許多顯而易見的臨床優勢，例如提高診斷速度和減輕患者負擔，但其市場發展仍面臨高昂的資金投入等重大障礙。購置和維護先進光學成像設備的成本高昂，限制了其普及，尤其是在醫療基礎設施尚未完善且小規模的醫療機構。這種資金限制迫使醫療機構進行嚴格的成本效益分析，導致這些診斷系統的採購速度緩慢，並阻礙了其更廣泛的市場滲透。

市場促進因素

光學成像技術的進步正從根本上改變光學活體組織切片領域，提高了診斷準確率，並實現了即時組織評估。螢光導引手術和先進的光學同調斷層掃描（OCT）等創新技術使外科醫生能夠在手術中可視化腫瘤邊緣，從而最大限度地減少再次手術的需要。近期，一種結合了藥物和醫療設備技術的先進成像平台獲得監管部門核准，這便是該領域進步的一個顯著例證，該平台具有卓越的檢測能力。根據 Lumicell 公司 2024 年 4 月發布的新聞稿，新核准的LumiSystem 在乳癌乳房保留手術中檢測殘留癌的診斷準確率高達 84%，解決了傳統組織病理學面臨的一大難題，並推動了市場成長。

全球癌症和慢性疾病的日益普及是推動光學活體組織切片系統普及應用的主要因素。隨著惡性腫瘤發病率的上升，迫切需要快速、非侵入性的診斷工具，以便在不耗費傳統組織樣本處理時間的情況下，處理日益成長的患者數量。根據國際癌症研究機構（IARC）2024年2月發布的數據，預計到2050年，新增癌症病例將超過3,500萬例，比2022年的估計值增加77%。疾病負擔的快速成長與對先進診斷輔助設備的需求成長直接相關，Maunakea Technologies公司2023年銷售額成長42%至1050萬歐元便印證了這一點。該公司銷售成長的主要驅動力是市場對共聚焦雷射內視鏡解決方案日益成長的需求。

市場挑戰

高昂的資本投入是全球光學切片市場擴張的主要障礙。這些診斷系統的實施需要大量的初期投入，限制了預算有限的醫療機構使用。這種經濟負擔不僅包括初始購買成本，還包括日常維護、校準以及醫護人員的專業訓練費用。因此，小規模的社區醫院和診所往往會延後採用這項技術，而選擇更傳統、更經濟的診斷方法。這實際上限制了光學活體組織切片系統的應用範圍，使其僅限於資金雄厚的大型醫療中心。

這種經濟限制直接阻礙了市場滲透，延長了潛在買家的決策流程。醫療機構管理者被迫進行嚴格的成本效益分析，這往往導致採購延遲或採購申請被拒絕。醫療保健產業面臨的更廣泛的財務壓力進一步加劇了這種猶豫不決。例如，美國醫學會 (AMA) 指出，2024 年聯邦醫療保險醫師收費標準將下調 3.4%，造成了更具挑戰性的財政環境。報銷水準的降低限制了用於購買先進設備的自由支配資金，最終減緩了光學活體組織切片市場的整體成長速度。

市場趨勢

光學成像與機器人輔助手術系統的融合，透過將細胞級視覺化直接整合到機器人平台中，正在為精準手術建立一種新的範式。這種協同作用解決了術中切緣評估的關鍵難題，使外科醫生能夠在無需進行冰凍切片檢查的情況下識別潛在病變並保留健康組織。這種整合使得在經口機器人手術（TORS）等複雜手術過程中能夠進行即時決策，而識別腫瘤切緣在這些手術中尤其具有挑戰性。根據Maunakea Technologies公司2025年1月發布的新聞稿，一項採用這種整合方法的病例係列研究表明，外科醫生在所有病例中均實現了術後切緣陰性。

在將診斷工作流程整合到單一導管解決方案的臨床需求驅動下，多模態混合成像平台的商業化進程正在迅速推進。這些平台將高解析度結構影像（例如光同調斷層掃瞄(OCT)）與功能性生理測量資料融合，從而最佳化心臟病介入治療策略。這種整合透過同時提供形態學和生理學數據，最大限度地減少了導管更換次數，並提高了經經皮冠狀動脈介入治療 (PCI) 期間的決策效率。正如 SpectraWAVE 公司在 2025 年 10 月發布的新聞稿中所強調的，該公司憑藉其人工智慧驅動的 X1-FFR 平台，在短短兩年多的時間裡獲得了第五次 FDA核准。這印證了產業正加速向多功能一體化光學診斷工具轉型。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球光學切片市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（光同調斷層掃瞄（OCT）、雷射、紅外線、螢光、光譜學、其他）
    • 依應用領域（腫瘤科與非腫瘤科）
    • 按最終使用者（醫院/診所、癌症治療中心、學術/研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美光學切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲光學切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區光學切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲光學切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲光學切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球光學切片市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Mauna Kea Technologies
  • Boston Scientific Corporation
  • Olympus Corporation
  • Medtronic plc
  • Hologic, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Cook Medical
  • Cardinal Health, Inc.
  • NinePoint Medical, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 10689

The Global Optical Biopsy Market is projected to expand from USD 1.46 Billion in 2025 to USD 2.32 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.02%. Optical biopsy defines a non-invasive diagnostic method that leverages light-tissue interaction to capture real-time pathological data, thereby eliminating the requirement for physical tissue extraction. The market's growth is largely driven by the rising incidence of oncological conditions and the critical need for early disease detection, which demands frequent and less invasive diagnostic procedures. According to the American Cancer Society, an estimated 2,001,140 new cancer cases were anticipated in the United States in 2024, a rising disease burden that accelerates the demand for rapid diagnostic modalities capable of delivering immediate results for prompt treatment planning.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.46 Billion
Market Size 2031USD 2.32 Billion
CAGR 2026-20318.02%
Fastest Growing SegmentSpectroscopy
Largest MarketNorth America

Despite the clear clinical benefits regarding diagnostic speed and reduced patient trauma, the market encounters significant obstacles related to high capital requirements. The substantial costs involved in purchasing and maintaining sophisticated optical imaging instrumentation limit accessibility, particularly within developing healthcare infrastructures or smaller medical facilities. This financial constraint compels healthcare providers to conduct rigorous cost-benefit analyses, which ultimately slows the procurement rate of these diagnostic systems and hinders broader market penetration.

Market Driver

Technological advancements in optical imaging modalities are fundamentally transforming the optical biopsy landscape by improving diagnostic precision and facilitating real-time tissue assessment. Innovations such as fluorescence-guided surgery and advanced optical coherence tomography are minimizing the need for repeat procedures by enabling surgeons to visualize cancerous margins during operations. A notable example of this progress is the recent regulatory approval of advanced imaging platforms that combine drug-device technologies for superior detection; according to a Lumicell Inc. press release in April 2024, their newly approved LumiSystem demonstrated an 84% diagnostic accuracy in detecting residual cancer during breast-conserving surgery, addressing critical gaps in traditional histopathology and fostering market growth.

The escalating global prevalence of cancer and chronic diseases acts as a primary catalyst for the widespread adoption of optical biopsy systems. As malignancy rates rise, there is an urgent requirement for rapid, non-invasive diagnostic tools capable of handling growing patient volumes without the delays associated with physical tissue processing. Data from the International Agency for Research on Cancer (IARC) in February 2024 indicates that over 35 million new cancer cases are predicted for 2050, representing a 77% increase from 2022 estimates. This surging disease burden correlates directly with increased procurement of advanced diagnostic aids, as evidenced by Mauna Kea Technologies reporting a 42% sales increase to €10.5 million in 2023, driven largely by demand for its confocal laser endomicroscopy solutions.

Market Challenge

High capital requirements pose a substantial barrier to the expansion of the global optical biopsy market. The procurement of these diagnostic systems entails significant upfront expenditures, which restricts accessibility for healthcare facilities operating with limited budgets. This financial burden extends beyond the initial purchase price to include costs associated with regular maintenance, calibration, and the specialized training of medical personnel. Consequently, smaller community hospitals and clinics often defer the adoption of this technology in favor of traditional and more affordable diagnostic methods, effectively confining the usage of optical biopsy systems to large, well-funded medical centers.

This economic constraint directly impedes market penetration by prolonging the decision-making timeline for potential buyers. Healthcare administrators are compelled to perform rigorous cost-benefit analyses, which often results in delayed procurement or the rejection of purchase requests. This hesitation is intensified by broader financial pressures facing the medical sector; for instance, the American Medical Association noted in 2024 that the Medicare physician payment schedule was reduced by 3.4 percent, creating a tighter fiscal environment. This reduction in reimbursement levels limits the discretionary funds available for acquiring advanced instrumentation, thereby slowing the overall growth rate of the optical biopsy market.

Market Trends

The convergence of optical imaging with robotic-assisted surgical systems is establishing a new paradigm in precision surgery by integrating cellular-level visualization directly into robotic platforms. This synergy addresses the critical challenge of intraoperative margin assessment, allowing surgeons to identify occult disease and preserve healthy tissue without delaying the operation for frozen section analysis. The integration enables real-time decision-making during complex procedures, such as TransOral Robotic Surgery (TORS), where identifying tumor boundaries is notoriously difficult; according to a Mauna Kea Technologies press release in January 2025, a case series utilizing this integrated approach demonstrated that surgeons achieved clean margins post-surgery in 100% of cases.

The commercialization of multimodal hybrid imaging platforms is rapidly advancing, driven by the clinical need to consolidate diagnostic workflows into single-catheter solutions. These platforms merge high-resolution structural imaging, such as Optical Coherence Tomography (OCT), with functional physiology measurements to optimize intervention strategies in cardiology. This integration minimizes catheter exchanges and enhances decision-making efficiency during percutaneous coronary interventions by providing simultaneous morphological and physiological data. As highlighted in an October 2025 press release by SpectraWAVE, Inc., the company secured its fifth FDA clearance in just over two years for its AI-enabled X1-FFR platform, underscoring the accelerating industry shift toward versatile, all-in-one optical diagnostic tools.

Key Market Players

  • Mauna Kea Technologies
  • Boston Scientific Corporation
  • Olympus Corporation
  • Medtronic plc
  • Hologic, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Cook Medical
  • Cardinal Health, Inc.
  • NinePoint Medical, Inc.

Report Scope

In this report, the Global Optical Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Biopsy Market, By Technique

  • Optical Coherence Tomography (OCT)
  • Laser
  • Infrared
  • Fluorescence
  • Spectroscopy
  • Others

Optical Biopsy Market, By Application

  • Oncological
  • Non-Oncological

Optical Biopsy Market, By End User

  • Hospitals & Clinics
  • Cancer Care Centers
  • Academic & Research Institutes
  • Others

Optical Biopsy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Biopsy Market.

Available Customizations:

Global Optical Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technique (Optical Coherence Tomography (OCT), Laser, Infrared, Fluorescence, Spectroscopy, Others)
    • 5.2.2. By Application (Oncological v/s Non-Oncological)
    • 5.2.3. By End User (Hospitals & Clinics, Cancer Care Centers, Academic & Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Optical Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technique
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Optical Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technique
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Optical Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technique
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Optical Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technique
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Optical Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technique
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Optical Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technique
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Optical Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technique
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Optical Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technique
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Optical Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technique
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Optical Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technique
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Optical Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technique
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Optical Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technique
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Optical Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technique
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Optical Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technique
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Optical Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technique
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Optical Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technique
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Optical Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technique
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Optical Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technique
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Optical Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technique
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Optical Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technique
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Optical Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technique
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Optical Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technique
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Optical Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technique
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Optical Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technique
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Optical Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Mauna Kea Technologies
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boston Scientific Corporation
  • 15.3. Olympus Corporation
  • 15.4. Medtronic plc
  • 15.5. Hologic, Inc.
  • 15.6. Danaher Corporation
  • 15.7. Becton, Dickinson and Company
  • 15.8. Cook Medical
  • 15.9. Cardinal Health, Inc.
  • 15.10. NinePoint Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer